Basket cover image
10 handpicked stocks

High Yielding Stocks

Looking for income from your investments? These carefully selected companies have historically paid substantial dividends compared to their share prices. Our analysts have handpicked these stocks for their dividend potential.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock
Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at मई 7

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

IEP

Icahn Enterprises, L.P.

IEP

Current price

$8.41

OXLC

Oxford Lane Capital Corp.

OXLC

Current price

$3.43

MNR

MACH NATURAL RESOURCES L.P.

MNR

Current price

$13.83

About This Group of Stocks

1

Our Expert Thinking

These stocks offer attractive dividend yields relative to their current prices. From REITs and energy partnerships to financial services and shipping companies, they represent sectors that traditionally prioritize returning value to shareholders through regular dividend payments.

2

What You Need to Know

High-yield stocks can provide steady income, but they often come with higher risk profiles. These companies are currently undervalued compared to their historical dividend payments, suggesting potential value. Consider these as part of a balanced portfolio rather than your entire investment strategy.

3

Why These Stocks

We've selected companies across diverse sectors including REITs, natural resources, shipping, and financial services. Each has demonstrated a commitment to maintaining dividend payments, creating potential income opportunities for investors looking beyond just stock price appreciation.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+51.95%

Group Performance Snapshot

51.95%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 51.95% over the next year.

8 of 10

Stocks Rated Buy by Analysts

8 of 10 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

💰

Regular Income Potential

These high-yield stocks can provide regular dividend payments, creating a steady income stream that many investors find attractive compared to growth-only stocks.

🔍

Currently Undervalued

Our analysts believe these stocks may be undervalued relative to their dividend history, potentially offering both income and price appreciation if markets recognize their value.

🌍

Diverse Sector Exposure

From real estate and energy to shipping and financial services, this collection offers exposure to multiple dividend-focused sectors in a single convenient group.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.